Skip to main content

For Consumers

Janrain User Menu
0 items
Search

You are here

Home
>
Adult Conditions
>
Adult Special conditions
>
Gastrointestinal

Gastrointestinal Risk

For patients at higher risk for GI complications, TYLENOL® can be an appropriate choice.1-4 

In the stomach, NSAIDs inhibit cyclooxygenase-1 (COX-1)5

In the stomach, COX-1 plays an important role in gastric mucosal protection. NSAID inhibition of COX-1 can diminish this COX-1 mediated protective mechanism. This can lead to GI side effects such as irritation and bleeding.5

Because TYLENOL® does not interfere with COX-1 like NSAIDs, it does not irritate the stomach the way naproxen sodium or even ibuprofen can.1-4  

Watch how NSAIDs can increase GI risk5

Some comorbidities can increase the risk of NSAID-related GI bleeding4,6,7

The GI risks of NSAIDs are even greater in certain patients, including those on aspirin heart therapy and those on certain antiplatelet therapies.

TYLENOL® Extra Strength and Gastrointestinal complications

An appropriate analgesic option

For patients at higher risk for GI complications1-4

View product dosing
The safety and efficacy of acetaminophen chart

TYLENOL® is the #1 doctor-recommended brand of pain reliever

The safety and efficacy of acetaminophen are well established.

View studies

REFERENCES: 1. Hoftiezer JW, O’Laughlin JC, Ivey KJ. Effects of 24 hours of aspirin, Bufferin, paracetamol and placebo on normal human gastroduodenal mucosa. Gut. 1982;23(8):692-697. 2. Blot WJ, McLaughlin JK. Over the counter non-steroidal anti-inflammatory drugs and risk of gastrointestinal bleeding. J Epidemiol Biostat. 2000;5(2):137-142. 3. US National Library of Medicine. Naproxen. https://www.nlm.nih.gov/medlineplus/druginfo/meds/a681029.html. Revised July 15, 2016. Accessed May 12, 2017. 4. Frech EJ, Go MF. Treatment and chemoprevention of NSAID-associated gastrointestinal complications. Ther Clin Risk Manag. 2009;5(1):65-73. 5. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Circulation. 2008;118(8):1894-1909. 6. Abraham NS, Hlatky MA, Antman EM, et al. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Circulation. 2010;122:2619-2633. 7. Kovac SH, Saag KG, Curtis JR, Allison J. Association of health-related quality of life with dual use of prescription and over-the-counter nonsteroidal anti-inflammatory drugs. Arthritis Rheum. 2008;59(2):227-233.